Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. LEN

Go back to Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight

Piper Jaffray Cuts Bristol-Myers (BMY) PT, Raises Merck's (MRK) Following BMY's CM-026 Failure

August 8, 2016 6:37 AM EDT

Piper Jaffray analyst Richard Purkiss lowered his price target on Neutral-rated Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $69.00) following news Friday that its CheckMate-026 (CM-026) trial of Opdivo missed its primary endpoint in the treatment of PD-L1+ expressors (>5% PD-L1+,~55-60% of patients) in... More

Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint

August 5, 2016 8:21 AM EDT

Bristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at 5%. The company will complete a full evaluation of the... More